HE4 in gynecological cancers: report of a European investigators and experts meeting

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F12%3A%230000457" target="_blank" >RIV/00209805:_____/12:#0000457 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ncbi.nlm.nih.gov/pubmed?term=HE4%20Study%20Group%5BCorporate%20Author%5D" target="_blank" >http://www.ncbi.nlm.nih.gov/pubmed?term=HE4%20Study%20Group%5BCorporate%20Author%5D</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/cclm-2012-0373" target="_blank" >10.1515/cclm-2012-0373</a>

Jazyk výsledku

angličtina

Název v původním jazyce

HE4 in gynecological cancers: report of a European investigators and experts meeting

Popis výsledku v původním jazyce

The HE4 protein, which belongs to the "four disulfide" acid protein group, has emerged as one of the most promising biomarkers in gynecologic oncology. An expert meeting on the analytical and clinical performance of the quantitative determination of HE4was held in November 2011, involving 25 clinical and laboratory specialists from 16 European countries. The aim of the meeting was to present and discuss the results of recent studies on the use of HE4 and on the Risk of Ovarian Malignancy Algorithm (ROMA), which combines the results of HE4 and CA 125. The meeting was structured in separate sessions focusing on ovarian cancer risk stratification, differential diagnosis, prognosis and monitoring and with diagnosis and monitoring of endometrial cancer. Wepresent here a summary of the data and evidence, presented, together with consensus statements on the different topics, where available, and suggestions for further studies and evaluations required to establish optimal use of HE4, either

Název v anglickém jazyce

HE4 in gynecological cancers: report of a European investigators and experts meeting

Popis výsledku anglicky

The HE4 protein, which belongs to the "four disulfide" acid protein group, has emerged as one of the most promising biomarkers in gynecologic oncology. An expert meeting on the analytical and clinical performance of the quantitative determination of HE4was held in November 2011, involving 25 clinical and laboratory specialists from 16 European countries. The aim of the meeting was to present and discuss the results of recent studies on the use of HE4 and on the Risk of Ovarian Malignancy Algorithm (ROMA), which combines the results of HE4 and CA 125. The meeting was structured in separate sessions focusing on ovarian cancer risk stratification, differential diagnosis, prognosis and monitoring and with diagnosis and monitoring of endometrial cancer. Wepresent here a summary of the data and evidence, presented, together with consensus statements on the different topics, where available, and suggestions for further studies and evaluations required to establish optimal use of HE4, either

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Chemistry and Laboratory Medicine

ISSN

1434-6621

e-ISSN

—

Svazek periodika

50

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

10

Strana od-do

2127-2136

Kód UT WoS článku

000311899200008

EID výsledku v databázi Scopus

—